Chinese Journal of Tissue Engineering Research ›› 2013, Vol. 17 ›› Issue (24): 4473-4480.doi: 10.3969/j.issn.2095-4344.2013.24.015

Previous Articles     Next Articles

In vivo concentration gradient of basic fibroblast growth factor after coronary venous retrograde perfusion

Zhen Lei1, Wang Xiao1, Miu Huang-tai1, Qiao Shi-bin1, 2, Wu Xing-xin1, Qiao Yan3, Liu Bai-qiu3, Liu Xin-min3, Que Bin1, Nie Shao-ping1   

  1. 1 Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heat, Lung and Blood Vessel Diseases, Beijing  100029, China
    2 Department of Cardiology, People’s Hospital of Rizhao, Rizhao  276826, Shandong Province, China
    3 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing  100029, China
  • Received:2013-02-16 Revised:2013-04-21 Online:2013-06-11 Published:2013-06-11
  • Contact: Nie Shao-ping, M.D., Chief physician, Doctoral supervisor, Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heat, Lung and Blood Vessel Diseases, Beijing 100029, China spnie@126.com
  • About author:Zhen Lei★, Master, Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heat, Lung and Blood Vessel Diseases, Beijing 100029, China
  • Supported by:

    General Program of National Natural Science Foundation of China, No. 81070166*, 81270284*; General Program of Science and Technology Planning of Beijing Municipal Education Commission, No. KM201010025020*

PDF

693

Abstract:

BACKGROUND: In vitro studies have demonstrated that the concentration gradient of basic fibroblast growth factor can promote the migration and proliferation of stem cells. However, it is unclear whether in vivo basic fibroblast growth factor concentration gradient can be established by coronary venous retrograde perfusion.
OBJECTIVE: To evaluate the safety of coronary venous retrograde perfusion and establish the concentration gradient of basic fibroblast growth factor between coronary venous blood and target myocardium, and to investigate the time window of basic fibroblast growth factor concentration gradient after coronary venous retrograde perfusion.
METHODS: The acute myocardial infarction models were established with ligating method, and 1 week later, coronary venous retrograde perfusion of basic fibroblast growth factor was performed. After perfusion, the time of balloon dilation was 0, 5, 10 and 15 minutes. The animals were sacrificed immediately after balloon inflation lifting, and then the enzyme-linked immunosorbent assay was used to measure the concentration of basic fibroblast growth factor in the plasma, farcted myocardium and homogenates of myocardium in the infarct border zone. The basic fibroblast growth factor concentration gradient between the coronary venous blood and infarcted myocardium and myocardium in the infarct border zone was in vivo evaluated.  
RESULTS AND CONCLUSION: The success rate of coronary venous retrograde perfusion was 100%. No death, cardiac tamponade, or ventricular arrthythmia occurred. There was no significant difference in concentration of basic fibroblast growth factor between coronary venous blood and infarcted myocardium at 5 and 10 minutes after perfusion, while the concentration of basic fibroblast growth factor in the infarcted myocardium was higher than that in the coronary venous blood and myocardium in the infarct border zone. There was no significant difference in the concentration between two groups after balloon dilation for 15 minutes. The results indicate that after coronary venous retrograde perfusion of basic fibroblast growth factor, the time of balloon dilation was 5-10 minutes which can establish stable basic fibroblast growth factor concentration gradient between the coronary venous blood and infarcted myocardium, and the concentration is highest in the infarcted myocardium. The stem cell infusion in this time window can enhance its transitional vitality.

Key words: tissue construction, tissue construction and bioactive factors, ischemic heart disease, coronary venous retrograde perfusion, growth factor, stem cells, in vivo, concentration gradient, basic fibroblast growth factor, bone marrow mesenchymal stem cells, National Natural Science Foundation of China

CLC Number: